Seigo Nakamura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/764694/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma. Breast Cancer, 2022, 29, 610-617.	2.9	1
2	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precision Oncology, 2022, 6, e2000368.	3.0	9
3	Application of Personal Health Record in Enhancing the Quality of Life in Patients With Breast Cancer Who Received Adjuvant Hormonal Therapy. The Journal of Breast Health, 2022, 18, 155-162.	1.0	1
4	Differences in age at diagnosis of ovarian cancer for each <i>BRCA</i> mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy. Journal of Gynecologic Oncology, 2022, 33, .	2.2	7
5	Comparison between a new assay system, Elecsys® Anti‑p53, and conventional MESACUPâ,,¢ for the detection of serum anti‑p53 antibodies: A multi‑institutional study. Molecular and Clinical Oncology, 2022, 17, .	1.0	0
6	Diagnostic performance of dedicated breast positron emission tomography. Breast Cancer, 2022, 29, 1013-1021.	2.9	7
7	Diagnostic performance of coronal view in comparison with transverse view of three-dimensional automated breast ultrasound. Acta Radiologica, 2021, 62, 27-33.	1.1	3
8	The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database. Journal of Human Genetics, 2021, 66, 307-314.	2.3	32
9	How pregnancy and childbirth affect the working conditions and careers of women surgeons in Japan: findings of a nationwide survey conducted by the Japan Surgical Society. Surgery Today, 2021, 51, 309-321.	1.5	10
10	Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells. Antibodies, 2021, 10, 6.	2.5	10
11	Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. Cancer Science, 2021, 112, 1310-1319.	3.9	3
12	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Research and Treatment, 2021, 189, 455-461.	2.5	6
13	Frequency of highâ€risk hormone receptorâ€positive breast cancer patients was much higher in Japanese breast cancer patients with germline <i>BRCA1/2</i> mutations than in sporadic breast cancer patients. Breast Journal, 2021, 27, 188-190.	1.0	Ο
14	Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society. Breast Cancer, 2020, 27, 85-91.	2.9	7
15	Differences in perception of breast cancer treatment between patients, physicians, and nurses and unmet information needs in Japan. Supportive Care in Cancer, 2020, 28, 2331-2338.	2.2	15
16	Moving a neodymium magnet promotes the migration of a magnetic tracer and increases the monitoring counts on the skin surface of sentinel lymph nodes in breast cancer. BMC Medical Imaging, 2020, 20, 58.	2.7	10
17	Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome. Npj Breast Cancer, 2020, 6, 25.	5.2	21
18	High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician's choice—in the EMBRACE study. Breast Cancer, 2020, 27, 706-715.	2.9	41

SEIGO NAKAMURA

#	Article	IF	CITATIONS
19	The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer. Breast Cancer, 2020, 27, 586-593.	2.9	5
20	Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challenges. Pharmacogenomics, 2020, 21, 359-367.	1.3	8
21	Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan. International Journal of Clinical Oncology, 2019, 24, 1105-1110.	2.2	14
22	Magnetically Promoted Rapid Immunofluorescence Staining for Frozen Tissue Sections. Journal of Histochemistry and Cytochemistry, 2019, 67, 575-587.	2.5	11
23	Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation <i>BRCA1</i> L63X. Oncotarget, 2019, 10, 3276-3284.	1.8	18
24	Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy. , 2019, 2, 877-884.		0
25	Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy. Breast Cancer, 2018, 25, 43-49.	2.9	16
26	The Prognostic Effect of Changes in Tumor StageÂand Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast CancerÂSubtype. Clinical Breast Cancer, 2018, 18, e219-e229.	2.4	18
27	Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan. Journal of Human Genetics, 2018, 63, 447-457.	2.3	58
28	Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nature Communications, 2018, 9, 4083.	12.8	179
29	Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2â^' Early-stage Breast Cancer. Clinical Breast Cancer, 2018, 18, 474-480.	2.4	21
30	QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer. The Journal of Breast Health, 2018, 14, 194-198.	1.0	7
31	Diagnostic accuracy of contrast-enhanced spectral mammography in comparison to conventional full-field digital mammography in a population of women with dense breasts. Breast Cancer, 2017, 24, 104-110.	2.9	106
32	Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 841-849.	2.3	8
33	Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. Investigational New Drugs, 2017, 35, 791-799.	2.6	16
34	Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. Breast Cancer Research and Treatment, 2016, 160, 163-172.	2.5	50
35	Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004. Breast Cancer, 2016, 23, 39-49.	2.9	5
36	Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry. Cancer Medicine, 2016, 5, 1328-1340.	2.8	42

SEIGO NAKAMURA

#	Article	IF	CITATIONS
37	Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry. Breast Cancer Research and Treatment, 2016, 156, 485-494.	2.5	18
38	Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005. Breast Cancer, 2016, 23, 50-61.	2.9	5
39	Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006. Breast Cancer, 2016, 23, 62-72.	2.9	10
40	Safe and effective deodorization of malodorous fungating tumors using topical metronidazole 0.75Â% gel (GK567): a multicenter, open-label, phase III study (RDT.07.SRE.27013). Supportive Care in Cancer, 2016, 24, 2583-2590.	2.2	29
41	For choosing axillary treatment, and adjuvant hormonal treatment. Breast Cancer, 2016, 23, 167-169.	2.9	0
42	Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer. Clinical Breast Cancer, 2016, 16, 299-304.	2.4	39
43	Development of Support System for Breast Cancer PatientsManaging Side Effects through an Internet-Based System. Japanese Journal of Cancer and Chemotherapy, 2016, 43, 85-90.	0.2	1
44	Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer, 2015, 22, 235-244.	2.9	58
45	The β-catenin signaling pathway induces aggressive potential in breast cancer by up-regulating the chemokine CCL5. Experimental Cell Research, 2015, 338, 22-31.	2.6	27
46	Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer. Clinical Breast Cancer, 2014, 14, 191-197.	2.4	38
47	The negative prognostic impact of downstaging after neoadjuvant chemotherapy in patients with hormone-receptor positive breast cancer Journal of Clinical Oncology, 2013, 31, e11524-e11524.	1.6	0
48	Significance of Ki-67 Expression and Risk Category (St. Gallen 2007) in Elderly Breast Cancer Patients, with Emphasis on the Need for Postoperative Adjuvant Therapy. The Showa University Journal of Medical Sciences, 2011, 23, 153-164.	0.1	0